Incyte Remains Undervalued As Opzelura And Niktimvo Scale
Source: SeekingAlpha
2026-02-18 22:38:10 ET
Since my last article in August, "Incyte: Wall Street Underestimates Strength of Ruxolitinib Portfolio," Incyte shares ( INCY ) are up 19.1%....
Read the full article on Seeking Alpha
For further details see:
Incyte Remains Undervalued As Opzelura And Niktimvo Scale
Incyte Corporation
NASDAQ: INCY
INCY Trading
-2.27% G/L:
$94.97 Last:
509,619 Volume:
$96.23 Open:
INCY Latest News
March 06, 2026 04:42:00 pm
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
INCY Stock Data
$19,951,294,692
161,377,262
0.07%
384
N/A
Biotechnology & Life Sciences
Healthcare
US
Wilmington
